Study identifier:D5980R00097
ClinicalTrials.gov identifier:NCT06422676
EudraCT identifier:N/A
CTIS identifier:N/A
Open-label single-arm, non-interventional, multi-centre, cohort study for evaluation of clinical and patient reported outcomes in new users of BREZTRI (Budesonide / Glycopyrronium / Formoterol) in routine care settings
Chronic Obstructive Pulmonary Disease
N/A
No
-
All
4
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Mar 2025 by AstraZeneca
AstraZeneca
-
This is a retrospective-prospective, non-interventional, multi-centre study that will be conducted in routine clinical settings in Russia. Eligible patients with moderate to severe COPD routinely treated with BREZTRI will be observed according to routine clinical practice for up to 24 weeks.
Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent airflow limitation that is usually progresses and is a consequence of a chronic inflammatory response of the respiratory pathways and lung tissue to the effects of inhaled harmful particles or gases. Exacerbations and comorbid conditions are an integral part of the disease and contribute significantly to the clinical picture and prognosis [1]. Patient-reported outcomes (both symptom-based and health-related quality of life-specific) are essential to evaluate symptoms, impact of symptoms on activities of daily living, and treatment response in COPD patients [12]. There is a need to evaluate the patient-reported outcomes during a triple therapy with budesonide + glycopyrronium bromide + formoterol (Breztri) in a real-life clinical practice. The aim of the study is to evaluate clinical and patient-reported outcomes of treatment with BREZTRI through effectiveness measures assessed pre- and post-treatment initiation and safety monitoring. The study results will be interpreted in the context of an open label, single arm study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.
Location
Location
Moscow, Russian Federation
Location
Yekaterinburg, Russian Federation
Location
Saint-Petersburg, Russian Federation
Location
Krasnodar, Russian Federation
Location
Ufa, Russian Federation
Location
Novosibirsk, Russian Federation
Location
Rostov-on-Don, Russian Federation
Location
Omsk, Russian Federation
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.